NCT04425252View on ClinicalTrials.gov

Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

December 29, 2020

Study Completion Date

January 12, 2021

Conditions
COVID-19
Interventions
DRUG

Brequinar

DHODH inhibitor, 100 mg daily x 5 days

OTHER

Standard of Care

Standard of Care per institutional guidelines for COVID-19 patients

Trial Locations (5)

19140

Temple University, Philadelphia

32207

Baptist Medical Center, Jacksonville

33606

University of South Florida/Tampa General, Tampa

87106

University of New Mexico, Albuquerque

06102

Hartford Hospital, Hartford

Sponsors
All Listed Sponsors
lead

Clear Creek Bio, Inc.

INDUSTRY